Amgen Czech Republic - EBITDA Growth

Amgen CR`s EBITDA Growth reached 26.3 % in 2017. This is 263 % less than in the previous year.

$1.99

Buy EBITDA Growth data for Amgen Czech Republic.

$19.99

Buy all data for Amgen Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

Company Unit 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic ... ... ... ... ...           50.4 -36.1 10.4 32.3 -15.0    
Bayer Czech Republic ... ... ...               -0.531 -33.0 20.7 5.62 17.5    
GlaxoSmithKline Czech Republic ... ... ...               27.4 -24.7 -19.4 -26.0 -0.486    
Merck Czech Republic ... ...                 170 24.9 -41.2 8.97 78.8    
Novartis Czech Republic                     3.11 13.4 2.54 57.5 15.7    
Pfizer Czech Republic ... ...                 93.1 -79.0 160 -0.368 -35.9    
Roche Czech Republic ... ... ...               -18.2 -1.49 60.6 -19.3 -21.0   ...
Sanofi-Aventis Czech Republic ... ... ... ...             26.7 -10.9 22.2 -82.8 455    
Servier Czech Republic ... ... ... ... ... ... ... ... ... ... ... ... 4.70 3.39 14.6    
Walmark ... ... ...               14.2 -56.9 -15.1 70.2 -212